Friedrich-Wilhelm Kuehne acquired the manufacturing facility in Germany and the intellectual property related to WF10 drug from Crescita Therapeutics, Inc. for a nominal consideration.

Friedrich-Wilhelm Kuehne acquired Nuvo Manufacturing GmbH from Crescita Therapeutics, Inc. (TSX:CTX) for a nominal consideration on July 11, 2016. The divestiture is part of Crescita Therapeutics’ plan to wind down its immunology group and reduce cash burn. In addition, under the terms of the agreement, the balance of Dr. Kuehne’s consulting fees were paid in full. Friedrich-Wilhelm Kuehne completed the acquisition of Nuvo Manufacturing GmbH from Crescita Therapeutics, Inc. (TSX:CTX) on July 11, 2016.